Home
Science and IP
Investors
Our Team
Events
News Releases
Contact
NASDAQ: CMND
FWB: CWY0
News Releases
Below are the latest News Releases for Clearmind Medicine Inc.
27
April
2023
Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
Read More
21
April
2023
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
Read More
20
April
2023
Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial
Read More
6
April
2023
Clearmind Medicine Closes US$3.5 Million Public Offering
Read More
16
March
2023
Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
Read More
14
March
2023
Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D. to Scientific Advisory Board
Read More
22
February
2023
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
Read More
15
February
2023
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
Read More
8
February
2023
Israel-Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
Read More
31
January
2023
Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
Read More
25
January
2023
Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
Read More
19
January
2023
Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company
Read More
17
January
2023
Israel-Based Clearmind Announces Additional Positive Results from the its Pre-Clinical Study for Cocaine Addiction Treatment
Read More
10
January
2023
Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
Read More
5
January
2023
Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic-Derived Obesity Treatment in Pre-Clinical Trial
Read More
Previous
Next
